XYXian-Rui Yuan

Xian-Rui Yuan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xian-Rui Yuan has a total of 58 co-authors. Here are the top co-authors by number of shared publications:

  • Gelei Xiao

    Department of Neurosurgery, Xiangya Hospital Central South University Changsha Hunan China

    4 shared publications
  • Qing Liu

    The Institute of Skull Base Surgery and Neurooncology at Hunan, Xiangya Hospital, Central South University, Changsha, Hunan, China

    4 shared publications
  • Can Du

    The Institute of Skull Base Surgery and Neurooncology at Hunan, Xiangya Hospital, Central South University, Changsha, Hunan, China

    3 shared publications
  • Cheng-Yuan Feng

    The Institute of Skull Base Surgery and Neurooncology at Hunan, Xiangya Hospital, Central South University, Changsha, Hunan, China

    3 shared publications
  • Jian Yuan

    The Institute of Skull Base Surgery and Neuro-oncology at Hunan, Neurosurgery Institute of Central South University, 87 Xiangya Road, Changsha, Hunan, 410008, People's Republic of China

    3 shared publications
  • Xue-Jun Li

    The Institute of Skull Base Surgery and Neurooncology at Hunan, Xiangya Hospital, Central South University, Changsha, Hunan, China

    3 shared publications

Latest Publications

  • Corrigendum to “Microsurgical Management of Craniopharyngiomas via a Unilateral Subfrontal Approach: A Retrospective Study of 177 Continuous Cases” [World Neurosurgery 90 (2016) 454-468]

    by Can Du, Cheng-Yuan Feng, Xian-Rui Yuan, Qing Liu, Ze-Feng Peng, Xing-Jun Jiang, Xue-Jun Li, Ge-Lei Xiao, Yi-Feng Li, Tao Xiong

  • Open Access

    Clinical significance of FBXO17 gene expression in high-grade glioma

    by Di Du, Jian Yuan, Wencai Ma, Jing Ning, John N. Weinstein, Xianrui Yuan, Greg N. Fuller, Yuexin Liu

    High-grade gliomas (HGGs) exhibit marked heterogeneity in clinical behavior. The purpose of this study was to identify a novel biomarker that predicts patient outcome, which is helpful in HGG patient management. We analyzed gene expression profiles of 833 HGG cases, representing the largest patient population ever reported. Using the data set from the Cancer Genome Atlas (TCGA) and random partitioning approach, we performed Cox proportional hazards model analysis to identify novel prognostic mRNAs in HGG. The predictive capability was further assessed via multivariate analysis and validated in 4 additional data sets. The Kaplan-Meier method was used to evaluate survival difference between dichotomic groups of patients. Correlation of gene expression and DNA methylation was evaluated via Student’s t-test. Patients with elevated FBXO17 expression had a significantly shorter overall survival (OS) (P = 0.0011). After adjustment by IDH1 mutation, sex, and patient age, FBXO17 gene expression was significantly associated with OS (HR = 1.29, 95% CI =1.04–1.59, P = 0.018). In addition, FBXO17 expression can significantly distinguish patients by OS not only among patients who received temozolomide chemotherapy (HR 1.35, 95% CI =1.12–1.64, P = 0.002) but also among those who did not (HR = 1.48, 95% CI =1.20–1.82, P < 0.0001). The significant association of FBXO17 gene expression with OS was further validated in four external data sets. We further found that FBXO17 endogenous expression is significantly contributable from its promoter methylation. Epigenetically modulated FBXO17 has a potential as a stratification factor for clinical decision-making in HGG.


  • Microsurgical Management of Craniopharyngiomas via a Unilateral Subfrontal Approach: A Retrospective Study of 177 Continuous Cases

    by Can Du, Cheng-Yuan Feng, Xian-Rui Yuan, Qing Liu, Ze-Feng Peng, Xing-Jun Jiang, Xue-Jun Li, Ge-Lei Xiao, Yi-Feng Li, Tao Xiong


  • Ectopic recurrence of pediatric craniopharyngiomas after gross total resection: a report of two cases and a review of the literature

    by Can Du, Cheng-Yuan Feng, Jian Yuan, Xianrui Yuan

    Ectopic recurrent craniopharyngioma is rare. We reported two pediatric cases and reviewed the related literature. We retrospectively studied 177 craniopharyngioma cases treated by the senior author (Yuan X) between years 2003 and 2013. Two ectopic recurrent craniopharyngiomas were identified. One was discovered under the right frontal lobe and the other was found in the fourth ventricle. Both patients underwent a second radical resection without complications. Then we conducted an extensive review of peer-reviewed, English-language literatures in the US National Library of Medicine, focusing on the treatment modalities, recurrent sites, and clinical outcomes. Sixty ectopic recurrent tumors have been reported so far (including this study). Thirty-three tumors were located in the previous surgical corridors and 27 were disseminated along the cerebrospinal fluid pathway. All recurrent tumors were surgically removed. The gross total resection (GTR) rates were 87 and 63 %, respectively. The natural course of recurrent ectopic craniopharyngiomas is progressive. GTR is the treatment of choice. Regular follow-ups are strongly recommended to detect any further recurrence.


  • Open Access

    Effect of ATorvastatin On Chronic subdural Hematoma (ATOCH): a study protocol for a randomized controlled trial

    by Rongcai Jiang, Dong Wang, Wai Sang Poon, Yi Cheng Lu, Xin Gang Li, Shi Guang Zhao, Ren Zhi Wang, Chao You, Xian Rui Yuan, Hua Feng, et al.

    Chronic subdural hematoma (CSDH) is a common disease that is more prevalent in older people. Surgical intervention is a safe treatment of choice. However, the recurrence rate is relatively high and the outcome is not always satisfactory among surgically treated patients. It is believed that aberrant angiogenesis and intracapsular inflammation contribute to the development of CSDH. Atorvastatin is reported to promote angiogenesis and suppress inflammation. We have recently shown that atorvastatin is effective to non-surgically reduce and eliminate CSDH with minimal side effects. Here, we report a clinical research trial protocol that is designed to evaluate the therapeutic effects of atorvastatin on CSDH. We have designed a multi-center, randomized, placebo-controlled, double blind clinical trial for evaluating the efficacy of oral atorvastatin in reducing CSDH. We have so far recruited 96 patients with CT-confirmed or MRI-confirmed CSDHs from 16 medical centers in China. These patients were originally recruited for the Oriental Neurosurgical Evidence-based Study Team (ONET) study. After informed consent is provided, patients are randomized to receive either atorvastatin (oral 20 mg/night for 8 weeks) or placebo (dextrin for 8 weeks); and followed for 16 weeks after the treatment. The primary outcome is the change in hematoma volume at the end of 8-week treatment. Secondary outcomes include: changes in 1) the hematoma volume at the 4th, 12th, and 24th weeks; 2) Markwalder’s Grading Scale and Glasgow Coma Scale (MGS-GCS); 3) Glasgow Outcome Score (GOS) and 4) Activities of Daily Life – the Barthel Index scale (ADL-BI). Safety will be assessed during the study by monitoring adverse events, laboratory tests, electrocardiography (ECG), measurements of vital signs (temperature, pulse, and blood pressure) and body weight. Results of this trial will provide critical information regarding whether atorvastatin is an effective and safe alternative to surgical treatment of CSDH. ClinicalTrials.gov Identifier – NCT02024373 The date of trial registration: 7 August 2013


  • MiRNA-125a-5p inhibits glioblastoma cell proliferation and promotes cell differentiation by targeting TAZ

    by Jian Yuan, Gelei Xiao, Gang Peng, Dingyang Liu, Zeyou Wang, Yiwei Liao, Qing Liu, Minghua Wu, Xianrui Yuan


  • Open Access

    Pituitary stalk management during the microsurgery of craniopharyngiomas

    by Gelei Xiao, Xianrui Yuan, Jian Yuan, Nadeem Akhtar Krumtally, Yifeng Li, Chengyuan Feng, Qing Liu, Zefeng Peng, Xuejun Li, Xiping Ding

    In the present study, 203 patients that had previously undergone microsurgery for craniopharyngiomas (CPs) between 1992 and 2012 were analyzed retrospectively on a long‑term follow‑up basis to investigate the differences in the recurrence rate and endocrine function between patients with preserved and resected pituitary stalks. To summarize the possible outcomes of microsurgery, the 203 patients were divided into 2 groups: Group A that had preserved pituitary stalks and Group B that had undergone resections of the pituitary stalk. Tumor origins and the involvement of the pituitary stalk during surgery were observed. From 2010 onwards, an ultra‑electron microscope was used postoperatively to detect whether pituitary stalk specimens were infiltrated or invaded with tumor cells. Long‑term follow‑up observations of the patients included tumor recurrence, postoperative endocrine dysfunction and visual acuity and field. Among the 203 patients, 175 patients received gross‑total resection (GTR) (175/203, 86.2%), 28 patients underwent subtotal resection (28/203, 13.8%) and 34 patients had surgery that preserved the pituitary stalk (34/203, 16.7%). There was no significant difference in the recurrence rate between Group A (4/34, 11.8%) and the patients in Group B (10/123, 8.1%) who underwent GTR and also received follow‑ups. Of the 157 patients who were followed up, 91 individuals underwent endocrine evaluation and the outcome was divided into normal, satisfactory and poor grades. The results for Group A were 5, 18 and 0, respectively, while the results for Group B were 1, 60 and 7, respectively, which showed a statistically significant difference between the groups. Pituitary stalk specimens of 15 patients were studied postoperatively using an ultra‑electron microscope and all samples showed tumor cells had invaded the pituitary stalk (15/15, 100%). Total resections of CPs with the pituitary stalk were recommended if the pituitary stalk was intraoperatively invaded. In cases where the pituitary stalk was not involved, microsurgical excisions preserving the pituitary stalk were preferred, as there was no significant increase in the recurrence rate and the patients experienced less endocrine dysfunction.


  • Tumstatin transfected into human glioma cell line U251 represses tumor growth by inhibiting angiogenesis

    by Hong-Xing Ye, Yu Yao, Xin-Jun Jiang, Xian-Rui Yuan

    Background: Angiogenesis is a prerequisite for tumor growth and plays an important role in rapidly growing tumors, such as malignant gliomas. A variety of factors controlling the angiogenic balance have been described, and among these, the endogenous inhibitor of angiogenesis, tumstatin, has drawn considerable attention. The current study investigated whether expression of tumstatin by glioma cells could alter this balance and prevent tumor formation. Methods: We engineered stable transfectants from human glioma cell line U251 to constitutively secrete a human tumstatin protein with c-myc and polyhistidine tags. Production and secretion of the tumstatin-c-myc-His fusion protein by tumstatin-transfected cells were confirmed by Western blotting analysis. In the present study, we identify the anti-angiogenic capacity of tumstatin using several in vitro and in vivo assays. Student's t-test and one-way analysis of variance (ANOVA) test were used to determine the statistical significance in this study. Results: The tumstatin transfectants and control transfectants (stably transfected with a control plasmid) had similar in vitro growth rates compared to their parental cell lines. However, the conditioned medium from the tumstatin transfected tumor cells significantly inhibits proliferation and causes apoptosis of endothelial cells. It also inhibits tube formation of endothelial cells on Matrigel. Examination of armpit tumors arising from cells overexpressing tumstatin repress the growth of tumor, accompanying the decreased density of CD31 positive vessels in tumors ((5.62±1.32)/HP), compared to the control-transfectants group ((23.84+1.71)/HP) and wild type U251 glioma cells group ((29.33+4.45)/HP). Conclusion: Anti-angiogenic gene therapy using human tumstatin gene may be an effective strategy for the treatment of glioma.


  • Expression and clinical significance of EGFL7 in malignant glioma

    by Chun-Hai Huang, Xue-Jun Li, Yi-Zeng Zhou, Yong Luo, Cui Li, Xian-Rui Yuan

    Tumor angiogenesis is an important factor for the continuous growth of human malignancies and can be used to predict the prognosis for patients. In the current study, we examined the expression of EGF-like domain 7 (EGFL7), an endothelial cell-derived secreted factor, in malignant gliomas and explored its clinical significance. We determined the steady-state mRNA levels of EGFL7 from 36 fresh glioma samples by semi-quantitative RT–PCR and the protein levels from 45 paraffin-embedded glioma samples by immunohistochemistry, respectively. Normal brain tissues from 10 patients with brain trauma were used as control. We also analyzed the correlations between the expression levels of EGFL7 and various clinical parameters, including patient gender, age, tumor grade, tumor proliferation marker Ki-67, and microvessel density (MVD). We found that EGFL7 was not detectable in normal brain tissues, but was up-regulated in both tumor cells and vascular endothelial cells within malignant glioma. The expression level of EGFL7 in malignant glioma significantly correlated with the tumor grade, Ki-67 expression and MVD (P < 0.01). Our data suggest that EGFL7 expression is a novel predictive factor for the clinical progression of malignant glioma, and may constitute a therapeutic target for anti-angiogenesis therapy in patients with the disease.